SciSparc Ltd. filings document foreign private issuer disclosures for a clinical-stage pharmaceutical company with ordinary shares listed on Nasdaq. The record includes Form 6-K reports and Form 20-F references covering NeuroThera Labs patent and clinical-regulatory updates, cannabinoid-based drug programs, the MUSE endoscopic-system IP portfolio, and hemp seed oil-based product operations.
The company’s SEC materials also describe capital-structure and financing matters, including convertible promissory notes, warrants, resale registration statements, Form F-3 and Form S-8 incorporation, shareholder meeting approvals, reverse-share-split mechanics, Nasdaq continued-listing compliance, governance matters and risk-related disclosure categories.
SciSparc Ltd. (SPRC) reported that it is advancing its strategic focus on the Agentic AI market by appointing Prof. Carmel Domshlak, an internationally recognized AI expert and Technion professor, to its newly established Scientific Advisory Board for AI and Cybersecurity, effective September 1, 2026.
The company states that his appointment is part of its efforts to build a strong scientific and technical foundation as it evaluates technologies, companies and potential opportunities across the Agentic AI ecosystem. SciSparc continues to operate its core clinical-stage cannabinoid pharmaceutical programs through subsidiary NeuroThera while exploring this new AI-focused strategic direction.
SciSparc Ltd. (SPRC), through its subsidiary NeuroThera Labs Inc., reports progress in its collaboration with Clearmind Medicine Inc. via U.S. publication of a patent application covering a combination of MDMA and N-acylethanolamines (including PEA) for potential treatment of PTSD, anxiety and eating disorders. This expands a joint intellectual property portfolio that now includes thirteen published patent applications generated globally through the NeuroThera–Clearmind collaboration. The newly published application describes potential effects of PEA on MDMA’s therapeutic potency, dosing, side effects and therapeutic window, and is framed against the backdrop of the FDA’s July 14, 2026 final guidance on clinical development of psychedelic drugs, which explicitly includes MDMA. SciSparc also highlights its broader clinical-stage cannabinoid-based programs, including SCI-110 and SCI-210, and notes customary forward-looking statement risks.
SciSparc Ltd. (SPRC) filed an amended Form F-3 to register for resale up to 2,559,736 Ordinary Shares held by existing investors, not newly issued by the company. The registered shares consist of 2,040,964 shares issuable upon conversion of a $2.0 million Initial Promissory Note, 405,728 shares underlying an accompanying warrant, and 113,044 shares underlying a pre-funded warrant issued to Xylo Technologies Ltd. for an intellectual property acquisition.
Under a securities purchase agreement, SciSparc may sell up to $10 million in convertible promissory notes to the Notes Investor for an aggregate purchase price of $9 million, at the company’s discretion over time. As of this filing, SciSparc has received $1.8 million from the Initial Promissory Note and may receive up to an additional $7.2 million from future notes plus up to approximately $2.0 million if all warrants are exercised for cash, which it intends to use for working capital and general corporate purposes. Ordinary Shares outstanding were 580,973 as of August 19, 2026, and would be 3,140,709 if the Initial Promissory Note, warrant and pre-funded warrant were fully converted or exercised.
SciSparc Ltd. (SPRC) filed Amendment No. 1 to its Form 20-F mainly to replace the prior auditor’s report with the most recent reports from EY and Deloitte and to add Note 1(d), reflecting a 1-for-21 reverse share split effective July 3, 2025. The amendment does not change the underlying audited figures, other than this added note and related dual dating of the 2024 auditor’s opinion.
For 2025, SciSparc reported revenue of $856k, down from $1.3m in 2024, and a net loss of $12.6m, versus $7.5m in 2024. Cash and cash equivalents were $4.6m at December 31, 2025, but operating cash outflow was $4.1m. The auditors and management highlight substantial doubt about the company’s ability to continue as a going concern given accumulated losses and the need for additional financing. Results include a $6.0m impairment on loans to AutoMax after its financial distress, recurring impairments of the Amazon-brand intangible, and a $2.2m gain from selling the MitoCareX stake for cash and Nexentis shares. Throughout 2025 SciSparc raised equity, converted debentures and exercised warrants, increasing outstanding shares to 365,444.
SciSparc Ltd. (SPRC) reported that it invested in a financing round for its majority-owned subsidiary, NeuroThera Labs Inc. NeuroThera completed two tranches of non-brokered private placements raising C$5.4 million in gross proceeds.
SciSparc subscribed for 22,500,000 units at C$0.12 per unit, for a total investment of C$2.7 million. Each unit includes one NeuroThera common share and one warrant with an exercise price of C$0.16 per share, exercisable for 36 months. If NeuroThera’s shares are approved for listing on the Nasdaq Stock Market, the expiry date of 50% of unexercised warrants may be accelerated after written notice. Following the financing, SciSparc holds approximately 44.6% of NeuroThera’s issued and outstanding common shares, and states that its stake is valued at about C$30 million. NeuroThera plans to use the net proceeds for general working capital and other corporate and administrative expenses.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs Inc., reports that the Japanese Patent Office has granted NeuroThera a patent titled “Compositions and Methods for Potentiating Derivatives of 4-Aminophenols.” The patent covers pharmaceutical compositions and methods using proprietary combinations of 4-aminophenol derivatives (including paracetamol) with N-acylethanolamines.
These combinations are designed to enhance the analgesic and antipyretic performance of 4-aminophenol-based therapies, which NeuroThera believes may allow lower effective dosing and help address dose-related side-effect concerns. The company states that this grant strengthens NeuroThera’s intellectual property portfolio and represents a strategic milestone as it advances combination-therapy platforms for pain, fever, and related conditions across global markets. SciSparc highlights its clinical-stage programs based on THC and non-psychoactive CBD, and NeuroThera’s broader focus on central nervous system and other underserved conditions.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports the launch and progression of a Phase IIb clinical trial of SCI-110 at the Yale Child Study Center for adults with Tourette Syndrome. SCI-110 combines dronabinol with palmitoylethanolamide in a single oral dosage form aimed at reducing tics while limiting side effects.
The multicenter study also runs at Hannover Medical School in Germany and Tel Aviv Sourasky Medical Center in Israel and builds on Phase IIa results that showed an average 21% tic reduction across participants on the Yale Global Tic Severity Scale. The Phase IIb trial is randomized, double-blind, placebo-controlled and cross-over, enrolling patients aged 18–65 and assessing tic severity changes at weeks 12 and 26.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reports a technological milestone for NeuroThera’s quantum sampling workflow platform for clinical trials data analytics. The platform has demonstrated a complete end-to-end hybrid quantum-classical workflow in a quantum simulation environment using real-world clinical data.
The workflow integrates secure data ingestion and preparation, quantum-enabled analytical processing, and generation of biologically and clinically interpretable insights. It is designed to handle complex, high-dimensional biomedical datasets and apply quantum-inspired and quantum-enabled methods. Ongoing development plans include scaling supported datasets, optimizing quantum algorithms, and running performance studies, advanced through CliniQuantum Ltd., in which NeuroThera holds 54.01%.
SciSparc Ltd. announced that its board has decided to target the agentic artificial intelligence market and will establish a Scientific Advisory Board focused on AI and cybersecurity. The company is evaluating opportunities and holding discussions with several agentic AI companies.
Subsidiary NeuroThera Labs Inc. reported successful internal validation of a proprietary quantum sampling workflow for clinical trial data analysis, built on an S&P 500 company’s hybrid quantum-classical computing platform. The platform is being advanced through CliniQuantum, a quantum-focused initiative in which NeuroThera holds 54.01%.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs, reported the initiation of a Phase IIb clinical trial site at Hannover Medical School in Germany for SCI-110, a proprietary cannabinoid-based treatment candidate for adult Tourette Syndrome.
The randomized, double-blind, placebo-controlled, cross-over study will evaluate daily oral SCI-110 in patients aged 18-65, with primary endpoints based on changes in tic severity on the Yale Global Tic Severity Scale at weeks 12 and 26 versus baseline. The multicenter trial also includes the Yale Child Study Center in Connecticut and Tel Aviv Sourasky Medical Center in Israel, building on prior Phase IIa data that showed an average tic reduction of 21%.